Armata Pharmaceuticals strategically advances its bacteriophage-based therapies by integrating sophisticated systems across its operations. This includes the establishment of advanced cGMP manufacturing capabilities and the rigorous management of extensive clinical trial data. The company's unique approach centers on an in-house, bench-to-clinic development model, directly linking scientific discovery, production, and clinical validation within a unified framework. This operational strategy for Armata Pharmaceuticals' digital transformation makes it distinct in the biotechnology landscape.
This concerted drive toward systemic integration generates critical dependencies on data accuracy and workflow efficiency across complex processes. The transformation inherently creates challenges in maintaining data consistency between R&D, manufacturing, and clinical trial systems, risking delays in regulatory submissions and product commercialization. This document analyzes these core initiatives, identifying operational control points and potential breakdowns to guide seller engagement.
Armata Pharmaceuticals Snapshot
Headquarters: Los Angeles, California
Number of employees: 61
Public or private: Public
Business model: B2B
Website: http://www.armatapharma.com
Armata Pharmaceuticals ICP and Buying Roles
Armata Pharmaceuticals targets specialized biotech firms and large pharmaceutical companies involved in infectious disease research and clinical development. The company also collaborates with governmental and defense health agencies focusing on antimicrobial resistance.
Who drives buying decisions
-
Chief Medical Officer → Oversees clinical trial execution and data integrity.
-
VP, Operations → Manages manufacturing processes and facility commissioning.
-
Head of Regulatory Strategy and Operations → Directs FDA submissions and compliance activities.
-
VP, Quality Assurance → Ensures adherence to cGMP and GLP standards in production and clinical trials.
Key Digital Transformation Initiatives at Armata Pharmaceuticals (At a Glance)
-
Commissioning cGMP manufacturing facility for in-house phage production.
-
Managing clinical trial data across multiple Phase 2 studies.
-
Developing regulatory submission workflows for FDA interactions.
-
Integrating R&D data for structural biology and synthetic biology applications.
Where Armata Pharmaceuticals’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| Manufacturing Execution Systems (MES) | Advanced cGMP manufacturing operations: production batch records fail to integrate with quality control systems. | VP, Operations, VP, Quality Assurance | Standardize data capture and traceability between manufacturing and quality systems. |
| Advanced cGMP manufacturing operations: process deviations occur during automated fill and finish sequences. | VP, Operations | Enforce sequence adherence and error handling within automated production lines. | |
| Clinical Trial Management Systems (CTMS) | Clinical data management and analytics: patient data points contain inconsistencies across trial sites. | Chief Medical Officer, Clinical Operations Director | Validate incoming data streams for completeness and accuracy before aggregation. |
| Clinical data management and analytics: regulatory reporting extracts incorrect patient demographics from trial databases. | Head of Regulatory Strategy and Operations, Clinical Data Manager | Route validated data directly from source systems into regulatory reporting templates. | |
| Regulatory Information Management (RIM) Platforms | Regulatory information management system implementation: document versions diverge across submission components. | Head of Regulatory Strategy and Operations, Regulatory Affairs Lead | Centralize document control and versioning for all regulatory filings. |
| Regulatory information management system implementation: submission data fails to meet FDA eCTD format requirements. | Head of Regulatory Strategy and Operations | Validate electronic submission packages against agency specifications. | |
| Laboratory Information Management Systems (LIMS) | R&D data and bioinformatics platform development: experimental data from various instruments lacks consistent metadata tagging. | Head of Research and Development, Lab Manager | Standardize data annotation and storage protocols for research experiments. |
| R&D data and bioinformatics platform development: genomic sequencing results do not link to sample tracking information. | Head of Research and Development, Bioinformatics Scientist | Enforce bidirectional traceability between samples and their analytical outputs. | |
| Data Integration & Orchestration Platforms | Integrating R&D data: structural biology data does not propagate to clinical research databases. | Head of Research and Development, Head of IT | Standardize data schema and transfer protocols between disparate systems. |
| Advanced cGMP manufacturing operations: supply chain data does not integrate with production planning modules. | VP, Operations, Supply Chain Director | Centralize demand forecasting and material availability data for production scheduling. |
Identify when companies like Armata Pharmaceuticals are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this company’s digital transformation unique
Armata Pharmaceuticals deeply integrates its scientific research and manufacturing with clinical development, driven by the unique requirements of phage therapy. Their digital strategy heavily depends on maintaining end-to-end data integrity from initial phage discovery through to cGMP production and complex clinical trials. This holistic approach makes their transformation distinct, requiring specialized systems that can manage highly specific biological data and stringent regulatory compliance simultaneously. They heavily depend on tightly integrated quality and regulatory systems to manage their novel therapeutic pipeline.
Armata Pharmaceuticals’s Digital Transformation: Operational Breakdown
DT Initiative 1: Advanced cGMP Manufacturing Operations
What the company is doing
Armata Pharmaceuticals formally commissioned a state-of-the-art cGMP manufacturing facility in Los Angeles in November 2025. This facility includes advanced clean rooms, automated fill and finish capabilities, and dedicated quality control laboratories. The goal is to produce proprietary high-purity, multi-phage cocktails for clinical trials and commercialization.
Who owns this
-
VP, Operations
-
VP, Quality Assurance
-
Manufacturing Director
Where It Fails
- Manual data entry creates discrepancies between production logs and quality release forms.
- Automated equipment sensor data fails to transmit in real-time to central monitoring dashboards.
- Batch production records lack complete audit trails for every material input.
- Environmental monitoring systems do not consistently capture cleanroom parameter deviations.
Talk track
Noticed Armata Pharmaceuticals recently commissioned its cGMP manufacturing facility. Been looking at how some biotech firms are standardizing data capture from production lines instead of manual logging, can share what’s working if useful.
DT Initiative 2: Clinical Data Management and Analytics
What the company is doing
Armata Pharmaceuticals manages extensive data from multiple Phase 2 clinical trials for AP-PA02 and AP-SA02. This includes data on safety, tolerability, efficacy, and phage kinetics from studies like diSArm, Tailwind, and SWARM-P.a. The company uses this data to support regulatory discussions and advance candidates into Phase 3 studies.
Who owns this
-
Chief Medical Officer
-
Clinical Data Manager
-
Biostatistician
Where It Fails
- Data discrepancies appear across electronic data capture (EDC) systems from different clinical sites.
- Clinical trial patient enrollment data does not reconcile with central study progress trackers.
- Laboratory results from external vendors fail to integrate directly into the core clinical database.
- Investigator site monitoring reports contain missing or incomplete source data verification findings.
Talk track
Saw Armata Pharmaceuticals is advancing multiple clinical candidates through Phase 2 trials. Been looking at how some clinical teams are validating data inputs from diverse sources instead of reconciling errors later, happy to share what we’re seeing.
DT Initiative 3: Regulatory Information Management System Implementation
What the company is doing
Armata Pharmaceuticals actively engages with the FDA for its phage therapy candidates, securing Fast Track Designation for AP-SA02 and holding End-of-Phase 2 meetings. This involves preparing comprehensive Biologics License Application (BLA) documents and addressing Chemistry, Manufacturing, and Controls (CMC) comments. The company aims to accelerate product approval and patient access.
Who owns this
-
Head of Regulatory Strategy and Operations
-
Regulatory Affairs Lead
-
VP, Quality Assurance
Where It Fails
- Submission documents contain outdated information due to fragmented version control processes.
- FDA query responses lack consistent traceability to original source data.
- Chemistry, Manufacturing, and Controls (CMC) data fails to align with regulatory submission requirements.
- Electronic Common Technical Document (eCTD) modules display format errors before final assembly.
Talk track
Looks like Armata Pharmaceuticals frequently interacts with the FDA for regulatory milestones. Been seeing teams centralize document control for all submission components instead of managing fragmented versions, can share what’s working if useful.
DT Initiative 4: R&D Data and Bioinformatics Platform Development
What the company is doing
Armata Pharmaceuticals deepens its understanding of phage biology through structural analysis and synthetic biology. This involves complex research to enhance knowledge of phage structure and function, including viral genome engineering. The company applies advanced scientific methods to discover natural phages and engineer them for tailored drug products.
Who owns this
-
Head of Research and Development
-
Bioinformatics Scientist
-
Lab Manager
Where It Fails
- Genomic sequencing data lacks standardized annotation for downstream bioinformatics analysis.
- Experimental results from various lab instruments do not automatically populate centralized databases.
- Phage characterization data exhibits inconsistencies across different research projects.
- Synthetic biology design parameters fail to link directly to actual construct performance data.
Talk track
Noticed Armata Pharmaceuticals invests in structural biology and synthetic biology for R&D. Been looking at how some research teams are standardizing data annotation for genomic information instead of manual reconciliation, happy to share what we’re seeing.
Who Should Target Armata Pharmaceuticals Right Now
This account is relevant for:
- Manufacturing Execution System (MES) vendors
- Clinical Trial Management System (CTMS) providers
- Regulatory Information Management (RIM) platform vendors
- Laboratory Information Management System (LIMS) providers
- Bioinformatics and R&D data management solutions
- Quality Management System (QMS) software vendors
Not a fit for:
- Basic CRM systems without life sciences specialization
- Generic IT consulting without pharma regulatory expertise
- Standalone HR platforms with no integration capabilities
- Consumer-facing marketing automation tools
When Armata Pharmaceuticals Is Worth Prioritizing
Prioritize if:
- You sell manufacturing execution systems that prevent production batch record discrepancies and integrate with quality control.
- You sell clinical trial management systems that validate incoming patient data and streamline regulatory reporting.
- You sell regulatory information management platforms that enforce document version control and ensure eCTD compliance.
- You sell laboratory information management systems that standardize experimental data annotation and link genomic results to samples.
- You sell data integration platforms that ensure consistent data flow between R&D, manufacturing, and clinical systems.
Deprioritize if:
- Your solution does not directly address data integrity, workflow automation, or compliance challenges in pharmaceutical development.
- Your product lacks specific features for cGMP manufacturing, clinical trials, or regulatory submissions in biotechnology.
- Your offering is not built for managing complex, highly regulated scientific and operational data.
Who Can Sell to Armata Pharmaceuticals Right Now
Manufacturing Execution System (MES)
Siemens Opcenter Execution Pharma - This company provides a comprehensive MES solution tailored for pharmaceutical manufacturing, integrating production processes with quality and compliance.
Why they are relevant: Armata's newly commissioned cGMP facility requires robust systems to prevent production batch record errors and ensure real-time data flow from automated equipment to quality systems. Siemens Opcenter can enforce process adherence and centralize production data for audit readiness.
Werum PAS-X MES - This company offers an industry-leading MES specifically designed to meet pharmaceutical and biotech regulatory requirements, including electronic batch records and deviation management.
Why they are relevant: Armata needs to ensure strict control over its phage manufacturing processes, where manual data entry or inconsistent record-keeping creates compliance risks. Werum PAS-X can automate batch record generation and manage deviations, ensuring data integrity for regulatory reviews.
Clinical Trial Management Systems (CTMS)
Medidata Rave Clinical Cloud - This company provides an integrated suite of clinical development solutions, including electronic data capture (EDC) and clinical trial management.
Why they are relevant: Armata manages data from multiple Phase 2 clinical trials, facing challenges with data consistency across sites and integration of external lab results. Medidata Rave can standardize data collection, validate inputs, and consolidate diverse clinical data streams for better analytics and regulatory preparation.
Veeva Clinical Operations Suite - This company offers cloud-based applications that unify clinical trial processes, data, and documents for faster execution and compliance.
Why they are relevant: Armata's ongoing clinical trials require efficient management of patient enrollment, site monitoring, and data verification. Veeva's suite can streamline these workflows, preventing data discrepancies and ensuring that monitoring reports are complete and accurate before submission.
Regulatory Information Management (RIM) Platforms
Veeva Vault RIM - This company provides a unified suite of applications for managing regulatory content, submissions, and product registrations throughout the lifecycle.
Why they are relevant: Armata's frequent interactions with the FDA and preparation for BLA submissions necessitate robust version control and adherence to eCTD formats. Veeva Vault RIM can centralize regulatory documents, manage submission components, and validate electronic packages against FDA specifications, preventing errors.
IQVIA RIM Smart - This company offers a comprehensive RIM solution that helps life sciences companies manage regulatory processes, information, and submissions globally.
Why they are relevant: Armata requires a system to consistently track regulatory commitments and responses to FDA queries. IQVIA RIM Smart can provide traceability for all regulatory interactions and ensure that Chemistry, Manufacturing, and Controls (CMC) data aligns perfectly with submission requirements.
R&D Data and Bioinformatics Platform
Benchling R&D Cloud - This company offers a cloud-based platform that unifies R&D workflows, including notebooks, LIMS, and molecular biology tools, for biotech companies.
Why they are relevant: Armata's focus on structural biology and synthetic biology generates complex experimental data that requires standardized annotation and centralized storage. Benchling can enforce consistent metadata tagging for genomic sequencing and automatically link experimental results to databases, improving data quality for research.
Thermo Fisher Scientific SampleManager LIMS - This company provides a robust LIMS that helps manage laboratory operations, samples, and results, ensuring data integrity and regulatory compliance.
Why they are relevant: Armata's research labs need to manage diverse experimental data and ensure traceability between samples and analytical outputs. SampleManager LIMS can automate data capture from lab instruments and enforce bidirectional links between samples and genomic analysis, preventing data fragmentation.
Final Take
Armata Pharmaceuticals scales its in-house phage therapy development, moving from late clinical trials to commercialization readiness. Breakdowns are visible in data consistency between disparate systems across manufacturing, clinical, and regulatory workflows. This account is a strong fit for solutions that enforce data integrity, automate compliance, and streamline information exchange within highly regulated life sciences operations.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.